Forbes contributors publish independent expert analyses and insights. Expert in AI for healthcare and longevity biotechnology Sep 27, 2023, 12:53pm EDT This article is more than 2 years old. The ...

Pharma’s return on investment (ROI) for research and development (R&D) is seeing a comeback after a record low in 2022, according to a recent report out of Deloitte. ROI on pharma R&D jumped to 4.1% ...

Paris (France), Madrid (Spain), October 3, 2014 - D&A PHARMA, a leading company in the Addiction Therapy field, is pleased to announce that it has signed an exclusive Supply, Licensing and ...

The pharmaceutical sector emerges into 2021 with exciting prospects. The race for a COVID-19 vaccine has stimulated innovation across the industry, but the sector has been building momentum for years.

The pharmaceutical industry has immense pressure to deliver advanced and novel therapies to patients worldwide but faces monumental challenges in drug development. On average, the journey from ...

LONDON--(BUSINESS WIRE)--Infiniti Research is the world's leading independent provider of strategic market intelligence solutions. Our market intelligence services are designed to connect your ...

What China is accomplishing in R&D “has implications for everyone playing in the R&D or innovation world,” McKinsey’s ...

I examine the applicability of relative R&D spending as a potential leading indicator of shareholder returns. In addition, the correlation of R&D spending with stock volatility and sales growth is ...

SALZBURG, Austria--(BUSINESS WIRE)--After successfully launching the D-mine ® Pump, an infusion device designed to provide precise continuous subcutaneous drug delivery for Parkinson´s patients, EVER ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced the successful closing of a ...

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST ...